Today: 1 July 2026
Browse Category

Pharmaceutical Industry 1 January 2026 - 16 January 2026

Atara Biotherapeutics stock dives on FDA EBVALLO rejection — what ATRA investors watch next

Atara Biotherapeutics stock dives on FDA EBVALLO rejection — what ATRA investors watch next

New York, Jan 12, 2026, 09:54 EST — Regular session Atara Biotherapeutics shares plunged about 56% to $6.03 in early trading after the U.S. Food and Drug Administration rejected its cell therapy tabelecleucel, marketed as EBVALLO in Europe, for a rare post-transplant cancer. The stock was volatile, swinging between $4.77 and $15.40 as investors reacted to the news, with volume exceeding 1.4 million shares.
12 January 2026
··
Thermo Fisher Scientific Inc stock: Weaverville phase-out plan hits tape ahead of JPM talk, Jan. 29 earnings

Thermo Fisher Scientific Inc stock: Weaverville phase-out plan hits tape ahead of JPM talk, Jan. 29 earnings

New York, Jan 10, 2026, 15:53 EST — The market has closed. Thermo Fisher Scientific is set to wind down its Weaverville-area facility in western North Carolina, according to a WARN notice filed with the state. The document reveals permanent layoffs starting as early as Dec. 31, 2026, with the eventual closure slated for late 2027. The company plans to cut 421 jobs at its 275 Aiken Road site, beginning the first wave of separations at the end of 2026 and continuing through the following year.
10 January 2026
···
AbbVie stock slips after $1.3 billion R&D charge and Revolution Medicines rumor — what investors watch next

AbbVie stock slips after $1.3 billion R&D charge and Revolution Medicines rumor — what investors watch next

New York, January 9, 2026, 20:18 — Market closed AbbVie Inc. shares dropped 1.8% on Friday, closing at $220.08. The decline followed the drugmaker’s decision to lower its 2025 earnings forecast and a denial of reports suggesting it was in talks to acquire cancer-drug developer Revolution Medicines. Since 2023, AbbVie has spent over $20 billion on acquisitions, aiming to offset the impact from Humira’s patent expiration.
10 January 2026
···
Eli Lilly stock slips on Zepbound-Taltz trial data as Ventyx deal, pricing debate loom

Eli Lilly stock slips on Zepbound-Taltz trial data as Ventyx deal, pricing debate loom

New York, Jan 8, 2026, 18:23 EST — After-hours Shares of Eli Lilly fell 2.1% on Thursday, trading between $1,070.16 and $1,133.06, and were last at $1,085.19 in after-hours activity after the drugmaker reported late-stage data on a Zepbound-Taltz combination in psoriatic arthritis. Lilly said 31.7% of patients on the combo met a dual goal — at least 50% lower disease activity and at least 10% weight loss after 36 weeks — compared with 0.8% on Taltz alone. Senior vice president Mark Genovese said the results support an “integrated treatment approach” for the inflammatory joint disease, which affects up to a third of people with psoriasis; nausea, diarrhea and constipation were among the most common side effects, Lilly said. Reuters
9 January 2026
··
Travere Therapeutics TVTX stock slides 5% as FDA decision on Filspari nears

Travere Therapeutics TVTX stock slides 5% as FDA decision on Filspari nears

New York, January 6, 2026, 15:27 — Regular session Nasdaq-listed Travere Therapeutics shares fell 5.3% to $36.09 in afternoon trading on Tuesday as investors looked toward next week’s U.S. FDA decision deadline on expanding its kidney drug Filspari into focal segmental glomerulosclerosis. The FDA’s Prescription Drug User Fee Act, or PDUFA, target action date is Jan. 13, and the stock has ranged from $34.88 to $39.16 in the session. SEC
6 January 2026
··
Axsome Therapeutics (AXSM) stock jumps after FDA sets April 30 decision for Alzheimer’s agitation drug

Axsome Therapeutics (AXSM) stock jumps after FDA sets April 30 decision for Alzheimer’s agitation drug

NEW YORK, January 1, 2026, 16:58 ET — Market closed Axsome Therapeutics shares jumped about 23% in the most recent session on Wednesday after the company said the U.S. Food and Drug Administration accepted its supplemental application for AXS-05 to treat agitation in Alzheimer’s disease and granted the filing priority review. The stock last traded at $182.64, after swinging between $148.79 and $184.40 on volume of about 3.1 million shares. Businessinsider
1 January 2026
···
Corcept Therapeutics (CORT) stock sinks after FDA rebuff; relacorilant outlook resets

Corcept Therapeutics (CORT) stock sinks after FDA rebuff; relacorilant outlook resets

NEW YORK, January 1, 2026, 10:45 ET — Market closed. Corcept Therapeutics Inc shares last ended Wednesday down 50.4% at $34.80 after the company said U.S. regulators were not ready to approve its drug relacorilant for a form of high blood pressure linked to hypercortisolism. U.S. stock markets are shut on Thursday for New Year’s Day. HCPLive
1 January 2026
··
Corcept stock plunges 50% after FDA rejects relacorilant in Cushing’s-related hypertension

Corcept stock plunges 50% after FDA rejects relacorilant in Cushing’s-related hypertension

NEW YORK, December 31, 2025, 18:31 ET — After-hours Corcept Therapeutics Inc shares sank about 50% in after-hours trading on Wednesday after the U.S. Food and Drug Administration declined to approve its oral drug relacorilant for a Cushing’s-related hypertension use. The stock was last at $34.80, down $35.39 from the prior close. Reuters
1 January 2026
··
1 2 3 4 5 6 … 9

Stock Market Today

  • Geiger Counter Ltd Buys Back 19,069 Shares at 63.95p Each
    July 1, 2026, 4:59 AM EDT. Geiger Counter Ltd repurchased 19,069 ordinary shares on June 30, 2026, paying an average of 63.95 pence per share. That price is about a 7% discount to fully diluted value. The company said the shares go into Treasury as part of an ongoing program. Since March 11, 2026, the group has repurchased 7,392,222 shares under the plan. After this buyback, Geiger Counter has 173,641,396 ordinary shares outstanding, with 118,410,966 voting shares and 55,230,430 in Treasury. The company said the buybacks are meant to keep capital structure and shareholder value on track.
Go toTop